Medicinal Bioconvergence Research Center

Seoul, South Korea

Medicinal Bioconvergence Research Center

Seoul, South Korea

Time filter

Source Type

Patent
Medicinal Bioconvergence Research Center and Korea Research Institute of Chemical Technology | Date: 2015-12-07

A maleic acid derivative represented by Chemical Formula 1 below or a pharmaceutically acceptable salt thereof:


The present invention relates to a method for scanning a cancer metastasis inhibitor by analyzing the activity of lysyl-tRNA synthetase (KRS) in a cancer cell line cultured in a three-dimensional collagen gel environment, and to a method for monitoring the dissemination of cancer cells from aggregated cancer cells, and the epithelial-mesenchymal transition, migration, invasion, and metastasis of cancer cells. Specifically, it was verified that, in the case where a cell line or a spheroidically aggregated cell line, in which KRS has been regulated to be expressed or unexpressed, was constructed by using various colorectal cancer cells including HCT116 cell line and then cultured in a two-dimensional environment, the incomplete epithelial-to-mesenchymal transition phenotype (incomplete ECM phenotype) was induced in the cell line inhibiting KRS expression, and the inhibition of KRS expression inhibited cell-extracellular matrix (ECM) adhesion and cell-ECM signaling activity. In addition, it was verified that, in the case where the constructed spheroid cell line was cultured in an aqueous environment or a three-dimensional collage gel culture environment, the inhibition of KRS expression induced cells into mesenchymal cells but failed to reach the disintegration of cell-cell adhesion; inhibited the cell-ECM adhesion and the related signaling activity, causing the inhibition of the dissemination of cells from spheroid cells cultured in a three-dimensional collagen gel culture environment; and failed to induce the dissemination of cells through TGF1 present in the cellular microenvironment. Thus, the present invention can be used as a method for screening a cancer metastasis inhibitor and a method for monitoring the migration, invasion and metastasis of cancer cells, and will be useful as one of the screening methods capable of creating low-cost, high-efficient added value at the time of pre-clinical tests required for drug development.


Patent
Medicinal Bioconvergence Research Center | Date: 2016-05-18

The present invention relates to a novel anticancer composition, and more specifically, to: an anticancer pharmaceutical composition comprising a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof; a method for preventing or treating cancer, comprising a step of administering an effective amount of a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof to an individual in need thereof; and a use of a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof for preparing an agent for preventing or treating cancer. The compound of the present invention inhibits, dependent on the concentration, the protein level of AIMP2-DX2, which is overexpressed in lung cancer cells, and inhibits, dependent on the concentration, the survival of cancer cells without acting on normal cells, and thus a pharmaceutical composition comprising the compound of the present invention or a pharmaceutically acceptable salt thereof can be used for preventing and treating cancer.


Patent
Medicinal Bioconvergence Research Center | Date: 2016-06-30

The present invention relates to an anti-lysyl-tRNA synthetase (KRS) antibody selectively binding to KRS, and a use thereof and, more specifically, to an antibody binding to human KRS or a fragment thereof, a method for producing the same, and a composition containing the same for diagnosing cancer, autoimmune diseases or inflammatory diseases. The antibody or fragment thereof of the present invention specifically binds to human KRS, and enables KRS detection and inhibition due to the absence of cross-linkage reactivity with the other proteins including the same ARS family, and thus the antibody or fragment thereof can be used to detect KRS and diagnose KRS-related diseases, i.e., cancer, autoimmune diseases or inflammatory diseases.


Patent
Medicinal Bioconvergence Research Center | Date: 2016-04-13

The present invention relates to a novel anticancer composition, and more specifically relates to a maleic acid derivative compound of Chemical Formula 1, to a production method for the compound, and to a pharmaceutical composition comprising the compound. The maleic acid derivative of the present invention suppresses the expression of AIMP2-DX2 and hence selectively suppresses the growth of cancer cell lines without acting on normal cells, and thus pharmaceutical compositions containing the maleic acid derivative of the present invention and pharmaceutically acceptable salts thereof as active ingredients can be used to prevent and treat cancer.


Patent
Medicinal Bioconvergence Research Center | Date: 2016-03-18

Described herein are an antibody specifically binding to AIMP2-DX2 protein, and a diagnostic kit for detecting cancer which comprises the antibody specific to the AIMP2-DX2.


Patent
Medicinal Bioconvergence Research Center | Date: 2015-02-25

The present invention relates to the use of a novel aminopyridine derivative to prevent or treat cancer, and more particularly to a carcinostatic composition including a compound of Formula 1 or a derivative thereof as an active principle. The compound of the present invention degrades the activation of AIMP2-D7C2 targeted by a novel anticancer drug so as to effectively in-duce destruction of cancer cells, thus effecting prevention and treatment of cancer. Therefore the compound of the present invention can be used to prevent and treat cancer.


Patent
Medicinal Bioconvergence Research Center | Date: 2015-06-01

Exemplary embodiments relate to a novel anticancer composition including a compound represented by chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient:


The present invention relates to a method for monitoring migration, invasion, and metastasis of cancer cells by observing the shape of cancer cells cultured in a three-dimensional environment and measuring the activity, expression, and changes in expression sites of proteins associated with invadopodia formation and metastasis, and the degradation of an extracellular matrix; and to a method for screening a cancer metastasis inhibitor. More specifically, it was verified that the reduction in c-Jun phosphorylation induced the increase in snail1 and the decrease in cortactin expression in the cells cultured in a three-dimensional environment and the expression regulation relations between the proteins were identical to those in breast cancer tissues obtained from patients. In addition, it was verified that, when breast cancer cells in a three-dimensional collagen gel environment were treated with a JNK inhibitor, the shape of the cells became longer; the contact region of the cells and the extracellular matrix became flattened and thinner; the migration of cancer cells was decreased; and the changes in protein expression was observed, such as the increase in TGF1 expression, the increases in smad2 and smad3 expression and activity, the increase in snail1 expression, the decrease in cortactin expression, and the resulting decrease in invadopodia formation. In addition, in a three-dimensional collagen gel environment, MT1-MMP besides the cortactin can be used as a marker of invadopodia, and it was verified that the inhibition of JNK led to the decrease in cortactin expression and the increase in snail1 expression, badly influenced the site and role of MT1-MMP to inhibit the formation of invadopodia, and inhibited the degrading activity of a collagen gel substrate. Thus, the present invention can be used as a method for monitoring migration, invasion, metastasis, and the degree of metastasis of cancer cells and a method for screening a cancer metastasis inhibitor, and will be useful as one of screening methods capable of creating low-cost, high-efficient added value at the time of pre-clinical tests required for drug development.


Patent
Medicinal Bioconvergence Research Center | Date: 2015-03-26

A method for screening an EMT inhibitor including: contacting EPRS, Snail1 protein, and a test agent; and measuring a change in a binding level between the EPRS and the Snail1 protein.

Loading Medicinal Bioconvergence Research Center collaborators
Loading Medicinal Bioconvergence Research Center collaborators